In 2025-2026, Japanese researchers achieved a major breakthrough in regenerative medicine by using induced pluripotent stem cells (iPSCs) to help a paralyzed patient stand and walk again. Conducted at Keio University, this world-first trial used stem cells to regenerate damaged spinal nerves, offering new hope for treating spinal cord injuries, Parkinson’s, and other degenerative diseases.
Key Breakthrough Details
- The Procedure: Researchers injected iPSC-derived neural stem cells directly into the damaged spinal cords of patients with severe, chronic spinal cord injuries.
- Clinical Results: In a trial of four patients, one participant regained the ability to stand independently and walk with assistance after previously being told recovery was impossible. Another patient regained movement in their limbs, with no serious side effects reported, confirming the safety of the treatment.
- Mechanism: The iPSCs, which are adult cells reprogrammed to act like embryonic cells, successfully grew into new neural tissue, repairing the broken nerve pathways.
- Broader Impact: This success, led by researchers like Hideyuki Okano at Keio University, marks a significant milestone in using regenerative medicine to treat previously incurable paralysis.
Other Ongoing Stem Cell Advancements in Japan
- Corneal Regeneration: Researchers have used stem cell sheets to treat corneal blindness, reducing the need for donor transplants.
- Heart Disease: Innovative “cellular patchwork” methods are being used to treat heart muscle damage, reducing symptoms in patients.
- Cancer & Parkinson’s: Studies are using CAR-T cells derived from iPSCs for targeted cancer treatment and exploring stem cell therapies to produce dopamine for Parkinson’s disease.
These achievements are supported by Japan’s unique regulatory framework, which allows for accelerated clinical testing of regenerative treatments.
Key Recent Breakthroughs & Studies (2024–2026):
- Blood Stem Cell Production (Sept 2024): Researchers at the Murdoch Children’s Research Institute (MCRI) developed a method to create human blood stem cells in the lab that closely resemble those in the human body, enhancing treatment options for leukemia and bone marrow disorders.
- Immune Cell Engineering (Jan 2026): The University of British Columbia (UBC) successfully produced functional helper T cells from stem cells, enabling off-the-shelf therapies for cancer and autoimmune diseases.
- Parkinson’s Disease Trials (May 2025): The Parkinson’s Foundation reports on trials using both induced pluripotent stem cells (iPSCs) and embryonic stem cells (hESCs) to transplant dopamine-producing neurons into the brain.
- Diabetes Treatment (Jan 2025): ScienceDirect published breakthroughs in generating functional human induced pluripotent stem cells (hiPSCs) for islet transplantation, providing a potential long-term solution for Type 2 diabetes.
- Enhanced Culturing Techniques (2024): Advancements in using laminin-511 allowed for large-scale, chemically defined production of stem cells, increasing reliability for therapeutic applications, noted in studies by CORDIS.
Areas of Active Research:
- Organoids: 3D structures developed from stem cells for disease modeling.
- CRISPR-Cas9: Genome editing for repairing genetic mutations in stem cells.
- CAR T-Cell Therapy: Advancements in treating hematologic cancers.
For ongoing and completed clinical trials, you can search the ClinicalTrials.gov database.
Shinya Yamanaka, Hiromitsu Nakauchi and Masayo Takahashi, three of Japan’s pioneering stem cell researchers © FT montage; Getty Images; Dreamstime
Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.comT&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here.
https://www.ft.com/content/254853b2-8f23-11e7-9084-d0c17942ba93
Dr Nakauchi, professor of stem cell therapy at the Tokyo University Institute of Medical Science, had not seen much of Genjiro Miwa since the two left Azabu High decades earlier. But he knew his old friend’s career had something to do with investment. “Look at what is happening! You finance people have done so many terrible things,” the regenerative medicine pioneer told him. “It’s time you finally did something to make the world better.”
